The discovery of somatic activating mutations in the epidermal growth factor receptor (EGFR) associated with dramatic responses to tyrosine kinase inhibitor (TKI) treatment resulted in precision medicine in the field of lung cancer therapeutics. The gene discussed is EGFR; the disease is lung cancer.